Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS ...

Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS ...

Aktien » Nachrichten » BIOGEN AKTIE » Biogen Inc.: Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at ...

Dravet syndrome is a severe developmental and epileptic encephalopathy (DEE) that is characterized by severe, recurrent seizures as well as significant cognitive and behavioral impairments.

Technology has also improved immunisation operations with the use of online appointment scheduling that automates ...

At the second annual HLTH Europe event in Amsterdam, Deep Dive editor Eloise McLennan sat down with ABIG Health founder and ...

Stoke Therapeutics advances RNA-based therapies for rare diseases like Dravet Syndrome.

The increasing incidence of genetic and rare diseases is a major factor driving revenue growth in the Antisense ...

It is estimated that CDD affects approximately 1 in 40,000 to 60,000 live births. Fintepla was first approved in 2020 to treat seizures associated with Dravet syndrome, a rare, severe form of ...

The global Oligonucleotide Synthesis Market is valued at USD 7.78 Billion in 2024 and is projected to reach a value of USD 21 ...